Pray For Paul » mellitus

Shouldn’t GLUCONEOGENESIS take place in a insulin dependent (diabetes mellitus) person,NOT Glycogenesis?

Fri, 16 Dec 2011 19:00:18 +0000

It seems to make sense that instead of Glycogenesis, Gluconeogenesis should take place because glucose is from a non-carb source, that being insulin, which is basically protein…

{answer}

What are the differences between type 1 diabetes mellitus and type 2 diabetes mellitus?

Sat, 04 Jun 2011 18:58:24 +0000

I’d prefer the answer come from the Marieb Anatomy and Physiology text book. If you can answer this, please cite the page number(s) you referenced.

{answer}

why does a lack or slow production of insulin cause diabetes mellitus?

Tue, 22 Feb 2011 18:58:57 +0000

a. insulin is required for exertion of glucose
b. insulin is required for glucose uptake
c. insulin is required for converting glucose to glycogen
d. insulin is required for synthesis of glucose

{answer}

What group of people are more likely to develop non-insulin dependent Diabetes mellitus II?

Wed, 24 Nov 2010 18:59:23 +0000

{answer}

Diabetes Mellitus – Cause, Effect & Diabetes Cure

Fri, 24 Sep 2010 06:58:51 +0000

qdmil.com Click this link to get free Diabetic Glucose Meter. Learn about the cause and effect of diabetes. This video gives you an idea of what is diabetes and how it effects the body.

Diabetes Mellitus: Advancing Treatment_part1

Sat, 04 Sep 2010 18:57:50 +0000

pcp.onlinemindanao.com Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries. More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.

Type 2 Diabetes Mellitus

Thu, 12 Aug 2010 12:59:34 +0000

Type 2 Diabetes Mellitus. 5 minutes lecture

Diabetes Mellitus: Advancing Treatment_part3

Sat, 24 Jul 2010 18:58:03 +0000

Diabetes Mellitus: Advancing Treatment_part2

Tue, 29 Jun 2010 06:56:27 +0000

www.pcp.onlinemindanao.com http www.JourneyPhilippines.net http Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries. More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.

Positive top-line results from Phenomix’ Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Sun, 25 Apr 2010 18:56:17 +0000

Positive top-line results from Phenomix’ Phase 3 trial of dutogliptin for Type 2 diabetes mellitus
Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.